» Articles » PMID: 15000423

Optimization of Individual and Population Designs Using Splus

Overview
Publisher Springer
Specialty Pharmacology
Date 2004 Mar 6
PMID 15000423
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

We address the problem of design optimization for individual and population pharmacokinetic studies. We develop Splus generic functions for pharmacokinetic design optimization: IFIM, a function for individual design optimization similar to the ADAPT II software, and PFIM_OPT, a function for population design optimization which is an extension of the Splus function PFIM for population design evaluation. Both evaluate and optimise designs using the Simplex algorithm. IFIM optimizes the sampling times in continuous intervals of times; PFIM_OPT optimizes either, for a given group structure of the population design, only the sampling times taken in some given continuous intervals or, both the sampling times and the group structure, performing then statistical optimization. A combined variance error model can be supplied with the possibility to include parameters of the error model as parameters to be estimated. The performance of the optimization with the Simplex algorithm is demonstrated with two pharmacokinetic examples: by comparison of the optimized designs to those of the ADAPT II software for IFIM, and to those obtained using a grid search or the Fedorov-Wynn algorithm for PFIM_OPT. The influence of the variance error model on design optimization was investigated. For a given total number of samples, different group structures of a population design are compared, showing their influence on the population design efficiency. The functions IFIM and PFIM_OPT offer new efficient solutions for the increasingly important task of optimization of individual or population pharmacokinetic designs.

Citing Articles

Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014).

Musuamba F, Manolis E, Holford N, Cheung S, Friberg L, Ogungbenro K CPT Pharmacometrics Syst Pharmacol. 2017; 6(7):418-429.

PMID: 28722322 PMC: 5529745. DOI: 10.1002/psp4.12196.


Statistical power calculations for mixed pharmacokinetic study designs using a population approach.

Kloprogge F, Simpson J, Day N, White N, Tarning J AAPS J. 2014; 16(5):1110-8.

PMID: 25011414 PMC: 4147042. DOI: 10.1208/s12248-014-9641-4.


Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.

Perera V, Bies R, Mo G, Dolton M, Carr V, McLachlan A Br J Clin Pharmacol. 2014; 78(4):800-14.

PMID: 24773369 PMC: 4239974. DOI: 10.1111/bcp.12410.


Utilization of optimal study design for maternal and fetal sheep propofol pharmacokinetics study: a preliminary study.

Sherwin C, Ngamprasertwong P, Sadhasivam S, Vinks A Curr Clin Pharmacol. 2013; 9(1):64-9.

PMID: 24219004 PMC: 5564389. DOI: 10.2174/1574884708666131111200417.


Basic concepts in population modeling, simulation, and model-based drug development.

Mould D, Upton R CPT Pharmacometrics Syst Pharmacol. 2013; 1:e6.

PMID: 23835886 PMC: 3606044. DOI: 10.1038/psp.2012.4.


References
1.
Retout S, Duffull S, Mentre F . Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput Methods Programs Biomed. 2001; 65(2):141-51. DOI: 10.1016/s0169-2607(00)00117-6. View

2.
Tod M, Rocchisani J . Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics. J Pharmacokinet Biopharm. 1997; 25(4):515-37. DOI: 10.1023/a:1025701327672. View

3.
Kelman A, Whiting B . Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm. 1990; 18(4):347-60. DOI: 10.1007/BF01062273. View

4.
Sheiner L, Wakefield J . Population modelling in drug development. Stat Methods Med Res. 2000; 8(3):183-93. DOI: 10.1177/096228029900800302. View

5.
Hooker A, Foracchia M, Dodds M, Vicini P . An evaluation of population D-optimal designs via pharmacokinetic simulations. Ann Biomed Eng. 2003; 31(1):98-111. DOI: 10.1114/1.1533074. View